Ovarian reserve is a total number of eggs present in the ovary. Some women suffer from a reduced ovarian reserve due to increased age or presence of pathology.
The older a woman gets, the more her ovarian reserve declines, meaning she has fewer eggs. The number of eggs remaining in her ovaries is decreasing until her ovarian reserve is used up and she enters menopause.
Some women are detected with a low ovarian reserve even in their 30’s or 40’s and this can negatively affect their fertility.
So far the only option left at this stage was IVF fertility treatment, which was often without success in these patients because of the insufficient number of eggs being collected.
SEGOVA ovarian rejuvenation is a program designed to help revitalize the ovaries and restore folliculogenesis, providing the new sources of eggs in previously egg-depleted ovaries.
SEGOVA is a group of methods based on biological therapy using autologous, natural, safe sources that can help retrieve the lost ovarian function and balance hormone production in hormone-secreting cells. It provides benefit by restoring the endocrine homeostasis and boosting the local ovarian environment to help achieve successful reproductive outcomes.
The sample of 93 patients aged 31 to 60 years (average age of 46,64 years) with diagnosis of infertility have completed SEGOVA ovarian rejuvenation and participated in a two year monitoring.
Percentage of women with presence of a follicle out of total number of patients.
Percentage out of total number of follicle positive patients (24,73% out of total number of patients ).
Percentage out of total number of oocyte positive patients (20,43% out of total number of patients).
Percentage out of total number of patients who had embryos (12,9% out of total number of patients) 25 embryos vitrified 36 embryos transferred.
Our doctors are available for a free no obligation consultation every day.
Professor Aleksandar Ljubić (pictured), MD PhD is the President of Forever Young Holding – international biotech holding dedicated to use and development of cutting edge biotechnology products and services with the aim to increase overall health, human longevity and quality of life.
He is a pioneer in invasive ultrasound guided fetal procedures, direct maturation of fetal lungs, inventor of method of prenatal hearing screening (PHS) (Sovilj-Ljubic), non-surgical fibroids treatment, and advanced NOTES laparoscopic procedures.
His main research areas are biotechnology in reproductive and perinatal medicine, assisted reproduction and minimally invasive reproductive surgery.
He has authored autologous in vitro genetic ovarian activation and is the author of the SEGOVA ovarian rejuvenation method. He was awarded a number of national and international recognitions and awards: First investigator Award (USA), Belgrade Science Award (Serbia), Sir William Lilley Award (WAPM).
Professor Ljubić was editor and co-editor in several scientific magazines, was President of the World Congress of perinatal medicine in 2017. He was the principal investigator in 11 scientific projects, published almost 500 publications – In peer-reviewed magazines – 62, with Citation index – 400.
Prof. Dr. Ljubić is a full professor at the DIU and visiting professor at Weill Cornell Medical School, USA. He was educated at Belgrade University with postgraduate education in the USA, Japan and Greece. For more than 25 years, he worked at the Medical School, University of Belgrade, Clinic for Obstetrics & Gynecology and Clinical Center of Serbia as a professor and a Head of Clinic.
Professor Ljubić is also a Deputy Secretary-General of World Association for Perinatal Medicine, Board member of the Fetus as a patient society and Associate member of International Academy of Perinatal Medicine.
Email Us
Quick Links